We evaluated the genetic impact of the amyotrophic lateral sclerosis (ALS) risk gene NIMA-related kinase 1 (NEK1) in a Belgian cohort of 278 patients with ALS (n=245) or ALS with frontotemporal dementia (ALS-FTD, n=33) and 609 control individuals. We identified two ALS patients carrying a loss-offunction (LOF) mutation, p.Leu854Tyrfs*2 and p.Tyr871Valfs*17, that were absent from the control group. A third LOF variant p.Ser1036* was present in two sibs with familial ALS, but also in an unrelated control person. Missense variants were common in both patients (3.6%) and controls (3.0%). The missense variant, p.Arg261His, which was previously associated with ALS risk, was detected with a minor allele frequency of 0.90% in patients compared to 0.33% in controls. Taken together, NEK1 LOF variants accounted for 1.1% of patients, although interpretation of pathogenicity and penetrance is complicated by the observation of occasional LOFs in unaffected individuals (0.16%). Furthermore enrichment of additional ALS gene mutations was observed in NEK1 carriers, suggestive of a 'second hit' model were NEK1 variants may modify disease presentation of driving mutations.
Interestingly, in DNA damage repair NEK1 was shown to interact with C21orf2, which was also recently associated to ALS risk (Fang et al., 2015; van Rheenen et al., 2016) .
In the present study we examined the impact of NEK1 in the genetic etiology of 278 Belgian unrelated patients suffering from pure ALS (N=245), or ALS with concomitant FTD (N=33).
MATERIALS and METHODS

Study cohort
The Belgian patient cohort screened in this study consisted of 278 index patients with clinical diagnosis of ALS (n=245, mean onset age 58 ± 11.6 years) and frontotemporal dementia together with ALS (ALS- 
RESULTS
We conducted full exonic re-sequencing of NEK1 in Belgian patients and control individuals. We (Fig. 2) .
The two frameshift variants, p.Leu854Tyrfs*2 and p.Tyr871Valfs*17 were each present in one isolated ALS patient and absent from controls ( 
NEK1 missense variants
The majority of identified variants were missense variants (Table 1 ). In patients, four missense variants were identified in 10/278 (3.6%) patients (Table 2) 
NEK1 polygenic carriers
Additional ALS gene mutations were present in seven out of 13 NEK1 patient carriers (table 2) . Taken together, the frequency of oligenic carriers in the NEK1 positive group of 54% (7/13), was significantly higher than what would be expected by chance based on the observed mutation frequency in the total patient cohort of 21% (57/278) (p=0.007).
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DISCUSSION
We explored the genetic contribution of NEK1 in a Belgian cohort of 278 ALS and ALS-FTD patients. We identified three LOF variants, of which one was novel (p.Leu854Tyrfs*2), giving a frequency of 1.1%, would be observed by chance based on the individual mutation frequencies of the known ALS genes that had an overall frequency of 21% in the total patient cohort. This enrichment of pathogenic ALS mutations in NEK1 variant carriers may fit into the 'two-hit' or 'multiple-hit' hypothesis that disease presentation results from accumulation of mutations (with variable penetrance). In that context, it is important to note that C9orf72 and SOD1 are known to be associated with reduced penetrance and wide ranges in disease onset. So although they may be the driver of the disease, the additional burden of a NEK1 variant may be needed for disease presentation or may accelerate it. An earlier disease onset was suggestive in the Arg261His patient with TARDBP p.Tyr374* nonsense mutation. This TARDBP mutation was previously described in an ALS patient with onset age of 63 years and predicted to generate a truncated TDP-43 protein that abolishes interaction of the C-terminal region of TDP-43 with heterogeneous nuclear ribonucleoproteins (hnRNPs) (Daoud et al., 2008) . In the present study, the TARDBP p.Tyr374* mutation was detected in an ALS patient with >15 years earlier onset age of 47 years, possibly due to the additional burden of the NEK1 Arg261His risk variant, although more observations are needed to substantiate this claim. The most striking example of oligenic carriers was the NEK1 p.Ser1036* nonsense variant that we identified in two affected sibs with family history of ALS and cognitive impairment that also segregated a C9orf72 repeat expansion and TUBA4A p.Thr38Met variant with early disease onsets of 47 and 52 years (Perrone and Nguyen et al., 2016) . In this family, the C9orf72 expansion is likely the most penetrant mutation, but a synergistic effect of NEK1 and TUBA4A on the phenotype cannot be excluded. • We investigated the NIMA-related kinase 1 (NEK1) gene in Belgian ALS patients.
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• NEK1 loss-of-function mutations were identified in 1% of ALS patients.
• NEK1 missense mutations were common in patients (3.6%) and controls (3.0%).
• The NEK1 p.Arg261His missense mutation was more frequent in patients.
• NEK1 variants more often concur with other ALS gene mutations, mostly C9orf72.
